# Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

> **NCT02907918** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 26 (actual)

## Conditions studied

- Breast Cancer
- Cancer of Breast
- Breast Carcinoma

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Letrozole
- **BIOLOGICAL:** Trastuzumab
- **DRUG:** Goserelin
- **PROCEDURE:** Breast surgery
- **PROCEDURE:** Research tumor biopsy
- **PROCEDURE:** Research bone marrow (OPTIONAL)
- **PROCEDURE:** Research blood sample
- **GENETIC:** Research blood for germline DNA
- **PROCEDURE:** Blood for detection of circulating tumor cells

## Key facts

- **NCT ID:** NCT02907918
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-30
- **Primary completion:** 2020-08-24
- **Final completion:** 2020-09-23
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Futility
- **Last updated:** 2021-09-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02907918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02907918, "Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02907918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*